SCHEMBL6201866

SCHEMBL6201866

O=C(Cl)c1cccnc1-c1ccc(C(F)(F)F)cc1

nearest known ligand 0.54

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 14/20 0.54
TLR7 Q9NYK1 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29978735 0.86 TDP1 (0.61) TRPV1
SCHEMBL4197626 0.86 TDP1 (0.61) TRPV1
Hydrochloric Acid SCHEMBL6201867 0.85 KDM4E (0.59) TRPV1
SCHEMBL5665026 0.85 TRPV1 (0.52) TRPV1
SCHEMBL4206899 0.81 TRPV1 (0.54) TRPV1
SCHEMBL2858512 0.78 TRPV1 (0.51) TRPV1
SCHEMBL3263627 0.78 KDM4E (0.65)
SCHEMBL403609 0.74 GAA (0.51)
SCHEMBL30477668 0.74 HDAC6 (0.48)
SCHEMBL2148942 0.74 HDAC6 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1259484-B1 CARBOXAMIDES USEFUL AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND OF APOLIPOPROTEIN B SECRETION NOVARTIS AG (CH) 2005-05-18 EP disclosed
US-6878707-B2 Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion NOVARTIS AG (CH) 2005-04-12 US disclosed
US-20030109700-A1 Carboxamides useful as inhinitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion NOVARTIS AG (CH) 2003-06-12 US disclosed
EP-1259484-A1 CARBOXAMIDES USEFUL AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND OF APOLIPOPROTEIN B SECRETION Novartis AG (CH) 2002-11-27 EP disclosed
WO-2001077077-A1 SUBSTITUTED (HETERO)ARYL CARBOXAMIDE DERIVATIVES AS MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) AND APOLIPOPROTEIN B (APO B) SECRETION NOVARTIS AG (CH) 2001-10-18 WO disclosed
WO-2001053260-A1 CARBOXAMIDES USEFUL AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND OF APOLIPOPROTEIN B SECRETION NOVARTIS AG (CH) 2001-07-26 WO disclosed
EP-1097129-A1 N-BENZOCYCLOALKYL-AMIDE DERIVATIVES AND THEIR USE AS MEDICAMENTS Novartis AG (CH) 2001-05-09 EP disclosed
US-6197798-B1 INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN NOVARTIS AG (CH) 2001-03-06 US disclosed
WO-2000005201-A1 N-BENZOCYCLOALKYL-AMIDE DERIVATIVES AND THEIR USE AS MEDICAMENTS NOVARTIS AG (CH) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109700-A1 Carboxamides useful as inhinitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion APOB, CETP, MTTP TRPV1 4333/4885TLR7 3671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.